AR065855A1 - Un medicamento para tratar la esquizofrenia que comprende cilostazol - Google Patents

Un medicamento para tratar la esquizofrenia que comprende cilostazol

Info

Publication number
AR065855A1
AR065855A1 ARP080101251A ARP080101251A AR065855A1 AR 065855 A1 AR065855 A1 AR 065855A1 AR P080101251 A ARP080101251 A AR P080101251A AR P080101251 A ARP080101251 A AR P080101251A AR 065855 A1 AR065855 A1 AR 065855A1
Authority
AR
Argentina
Prior art keywords
cilostazol
active component
skisophrenia
treat
salt
Prior art date
Application number
ARP080101251A
Other languages
English (en)
Inventor
Masaomi Iyo
Kenji Hashimoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR065855A1 publication Critical patent/AR065855A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Medicamento y método para prevenir y/o tratar la esquizofrenia que comprende como un componente activo cilostazol o una sal aceptable para uso farmacéutico del mismo. Reivindicacion 1: Un medicamento para prevenir y/o tratar la esquizofreniacaracterizado porque comprende como un componente activo un derivado de carboestirilo de la formula general (1) donde A es un grupo alquileno inferior, R es un grupo cicloalquilo, el enlace entre las posiciones 3 y 4 del esqueleto de carboestiriloes un enlace simple o un enlace doble, o una sal del mismo. Reivindicacion 2: El medicamento de la reivindicacion 1 caracterizado porque el componente activo es 6-[4-(1-ciclohexil-1H-tetrazol-5-il)butoxi]3,4-dihidrocarboestirilo o una sal delmismo.
ARP080101251A 2007-03-30 2008-03-27 Un medicamento para tratar la esquizofrenia que comprende cilostazol AR065855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007092596 2007-03-30

Publications (1)

Publication Number Publication Date
AR065855A1 true AR065855A1 (es) 2009-07-08

Family

ID=39521659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101251A AR065855A1 (es) 2007-03-30 2008-03-27 Un medicamento para tratar la esquizofrenia que comprende cilostazol

Country Status (11)

Country Link
US (1) US8431606B2 (es)
EP (1) EP2131838B1 (es)
JP (1) JP5299949B2 (es)
KR (1) KR101442295B1 (es)
CN (2) CN101677998B (es)
AR (1) AR065855A1 (es)
CA (1) CA2682347C (es)
ES (1) ES2393816T3 (es)
HK (1) HK1163526A1 (es)
TW (1) TW200848041A (es)
WO (1) WO2008123592A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012014993A1 (ja) * 2010-07-29 2013-09-12 国立大学法人 千葉大学 翻訳開始因子または翻訳伸長因子の増加剤、およびその医薬用途
AU2018367733B2 (en) * 2017-11-14 2024-06-20 Sk Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
TW202140039A (zh) * 2020-02-25 2021-11-01 日商大塚製藥股份有限公司 地西他濱及西屈嘧啶(cedazuridine)組合之固體口服劑型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3845059B2 (ja) 2000-08-14 2006-11-15 テバ ファーマシューティカル インダストリーズ リミティド シロスタゾールの製造方法
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
CN1222652C (zh) * 2002-05-31 2005-10-12 乐金电子(天津)电器有限公司 具有减震装置的洗衣机
TWI323660B (en) 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition

Also Published As

Publication number Publication date
CN101677998B (zh) 2012-05-09
KR101442295B1 (ko) 2014-09-22
CN101677998A (zh) 2010-03-24
US8431606B2 (en) 2013-04-30
KR20090126315A (ko) 2009-12-08
EP2131838A1 (en) 2009-12-16
TW200848041A (en) 2008-12-16
WO2008123592A1 (en) 2008-10-16
CN102349907A (zh) 2012-02-15
HK1163526A1 (en) 2012-09-14
JP5299949B2 (ja) 2013-09-25
US20100152247A1 (en) 2010-06-17
ES2393816T3 (es) 2012-12-28
EP2131838B1 (en) 2012-10-17
CA2682347C (en) 2014-07-15
CN102349907B (zh) 2013-06-05
JP2008273953A (ja) 2008-11-13
CA2682347A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
CO6251249A2 (es) Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
CL2015003442A1 (es) Derivados heterociclicos
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
BRPI0911444B8 (pt) benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
DOP2010000137A (es) Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
CL2012001402A1 (es) Composicion farmaceutica en suspension oftalmica acuosa de administracion topica que comprende polimero de carboxivinilo, galactomanana, borato, compuesto en nanoparticulas escasamente soluble, agentes para ajustar ph y tonicidad, conservante y quelante; metodo para tratar trastornos oftalmicos, metodo para mantener viscosidad.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
AR088204A1 (es) Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina
AR065855A1 (es) Un medicamento para tratar la esquizofrenia que comprende cilostazol
BR112015026631A2 (pt) compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero

Legal Events

Date Code Title Description
FB Suspension of granting procedure